Fresenius Kabi: No Launches From US Melrose Park Facility In 2021
Market Fears Warning Letter At Key US Facility
Fresenius Kabi saw a sales and earnings slump in its North America business in the final quarter of last year, which dragged heavily on the firm’s full-year operations. Management have conceded that one of those factors, manufacturing issues at its Melrose Park facility, will blow into 2021, with no product approvals or launches anticipated from the site.
You may also be interested in...
As Michael Sen takes the reins as CEO of Fresenius Kabi, Christian Pawlu has been recruited from Sandoz to head up the firm’s generics and complex formulations unit.
Fresenius Kabi has launched the first-ever generic version of Pfizer’s Foscavir in the US, with the product available immediately.
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).